Clinical-stage I-O company calls up B-MS VP

16 November 2017
mike_burgess_large

Canadian clinical-stage immuno-oncology (I-O) company Turnstone Biologics has named Mike Burgess (pictured) as president of research and development (R&D).

Dr Burgess joins from Bristol-Myers Squibb (NYSE: BMS), a big pharma frontrunner in the I-O space, where he was senior vice president of development across multiple therapeutic areas, including oncology.

In his new role, he will lead all R&D functions for Turnstone, which has been financed by Versant Ventures, OrbiMed, F-Prime Capital Partners and FACIT.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology